Non-invasive Biomarkers for Allograft Rejection
Q&A Handout: Covering speaker responses to questions not addressed during the live session.
Speakers:
Barbara Murphy, MD, MB, BAO, BCh, FRCPI • Murray M. Rosenberg Professor of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY
Peter Nickerson, BSc (Med), MD, FRCPC, FCAHS • Distinguished Professor of Internal Medicine and Immunology, University of Manitoba Max Rady College of Medicine, Winnipeg, MB
Moderator:
Peter Heeger, MD • Professor of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY
Objectives for the "Non-invasive Biomarkers for Allograft Rejection" webinar include:
- Discussing the role of Pre-Transplant HLA Molecular Mismatch as a Prognostic Biomarker of Primary Alloimmunity.
- Discussing the role of Pre-Transplant HLA Molecular Mismatch as a Predictive Biomarker of CNI-based therapy requirements to control Primary Alloimmunity.
- Discussing the impact of subclinical rejection on longterm survival and the need for non-invasive markers of allograft rejection.
- Discussing the role of peripheral gene expression for the detection of subclinical rejection.
AST would like to thank the Community of Transplant Scientists (COTS) and the Transplant Diagnostics Community of Practice (TxDx COP) for recommending biomarkers for allograft rejection as a topic for the 2019-2020 T3 series. Learn more about AST's COPs at www.myast.org/cops.